Product launch: Navigate immune responses with the new in situ assay kit Naveni® CD8/MHC-I
Uppsala, Sweden – February 28, 2024 – Dive into the secrets of immune responses with our in situ proximity ligation assay for the detection of CD8/MHC-I interactions, providing a nuanced perspective for a detailed and accurate portrayal of the immune response. This deeper understanding becomes the cornerstone for developing targeted immunotherapies, marking a potential leap forward in precision medicine for cancer treatment. Navinci has now developed the first commercial in situ proximity ligation assay for the specific detection of CD8/MHC-I interactions.
Learn more about CD8/MHC-I in the application note The Crucial Role of the CD8-MHC-I Interaction in Cellular Immune Responses.
Go to the Naveni® CD8/MHC-I product.
